Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech

Arcturus Therapeutics, an RNA interference tech company based out of Johnson & Johnson's ($JNJ) and Janssen Pharmaceutical's Janssen Labs, pulled in $1.3 million in a seed funding round from private investors in the U.S. and Canada. The San Diego company, founded in 2013, specializes in nanoparticle delivery technology that uses RNAi drugs to treat rare diseases. The founders, Joseph Payne and Pad Chivukula, who have worked on a novel RNAi treatment for fibrosis, have also created delivery platforms for drugs by DuPont, Merck ($MRK), Bristol-Myers Squibb ($BMY), Kalypsys and Nitto Denko. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…